Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-17
DOI
10.1038/s41591-021-01377-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adaptive immunity to SARS-CoV-2 and COVID-19
- (2021) Alessandro Sette et al. CELL
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Looking beyond COVID-19 vaccine phase 3 trials
- (2021) Jerome H. Kim et al. NATURE MEDICINE
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
- (2021) Raches Ella et al. LANCET INFECTIOUS DISEASES
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
- (2021) Zijun Wang et al. NATURE
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
- (2021) Rita E. Chen et al. NATURE MEDICINE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralizing Activity of BNT162b2-Elicited Serum
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
- (2021) Adam K. Wheatley et al. Nature Communications
- Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
- (2021) Wan Ni Chia et al. Lancet Microbe
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
- (2020) Jennifer A. Juno et al. NATURE MEDICINE
- Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
- (2020) F. Javier Ibarrondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
- (2020) Thomas F. Rogers et al. SCIENCE
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- (2020) Carolyn Rydyznski Moderbacher et al. CELL
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
- (2020) Lauren B. Rodda et al. CELL
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- (2020) Alicia T. Widge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
- (2020) Sheila F. Lumley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and “Universal” Vaccine Development
- (2019) Matthew J Memoli et al. CLINICAL INFECTIOUS DISEASES
- Heterogeneity and longevity of antibody memory to viruses and vaccines
- (2018) Alice Antia et al. PLOS BIOLOGY
- Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model
- (2016) Matthew J. Memoli et al. mBio
- International Laboratory Comparison of Influenza Microneutralization Assays for A(H1N1)pdm09, A(H3N2), and A(H5N1) Influenza Viruses by CONSISE
- (2015) Karen L. Laurie et al. Clinical and Vaccine Immunology
- Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
- (2015) Arnold S. Monto et al. JOURNAL OF INFECTIOUS DISEASES
- Confidence intervals for ratios of proportions: implications for selection ratios
- (2014) Ken Aho et al. Methods in Ecology and Evolution
- Who Invented the Delta Method?
- (2012) Jay M. Ver Hoef AMERICAN STATISTICIAN
- Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
- (2012) Laurent Coudeville et al. BMC Medical Research Methodology
- Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine
- (2012) Li-Wei Cheng et al. JOURNAL OF VIROLOGICAL METHODS
- Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children
- (2011) Steven Black et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Fast Implementation for Normal Mixed Effects Models With Censored Response
- (2009) Florin Vaida et al. JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation